SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.
The members of InterVenn’s executive leadership team will be available for one-on-one meetings at the event. A live and archived webcast of the event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ following the forum.
InterVenn Contact
Ramuné Carothers
Vice President, Corporate Communications
InterVenn Biosciences
media@venn.bio
Investor Contact
David Deuchler, CFA
Gilmartin Group
ir@venn.bio
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
